ClinicalTrials.gg
Active, not recruitingNCT05629377ARCHUpdated Jun 4, 2026

Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH)

An observational study in Hypothalamic Amenorrhea, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
90
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Planned enrollment
8th of 13
90 · median 111
Started
2023
with 1 other
Observational
13 of 43
3 open now
Registered
36th of 43
by date

Among the 43 studies in Amenorrhea with a site in United States, this one is the 8th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2023, is one of 13 observational ones, and was the 36th registered.

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

Hypothalamic amenorrhea (HA) occurs during reproductive years and results in stopped menstrual cycles and infertility which can be prolonged from months to years and is characterized by varying combinations of psychosocial stress, anxiety, high levels of physical activity, and/or weight loss. Data from our group indicates that one-third of women with HA (mean age: 27 yrs) have preclinical cardiovascular disease (CVD) measured noninvasively as vascular dysfunction and vascular inflammation. This study will use HA as a marker of fertility status for cardiovascular health and perform dense-phenotyping using remote patient monitoring (FitBit) and patient reported outcomes (questionnaires) to determine which HA phenotypes are related to preclinical CVD and inflammation.

03

Conditions studied

  • Hypothalamic Amenorrhea

Browse trials for

Keywords

  • Functional Hypothalamic Amenorrhea
  • Amenorrhea
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Premenopausal women with hypothalamic amenorrhea at Mayo Clinic Florida.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Secondary amenorrhea of 3 or more consecutive months duration
  • Include the screening hormones (eg, estradiol (E2) \< 50 pg/ml, Follicle-Stimulating Hormone (FSH) \<10 mIU/ml, and Luteinizing Hormone (LH) \< 10mIU/ml and other HA-defining hormones); or clinical diagnosis of HA by medical providers.
  • Pre-menopause status.
  • Able to give .

Exclusion criteria

Exclusion Criteria:

  • A diagnosis for secondary amenorrhea including prolactinoma, Polycystic Ovary Syndrome (PCOS), premature ovarian insufficiency, pituitary surgery, infection or infarction
  • Pregnancy
  • Psychotropic/illicit drug use
  • Mental/neurological/major psychological disorders (other than depression and anxiety).
  • Parturition/lactating in the last 6-12 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
90 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Hypothalamic Amenorrhea (HA) duration

    Duration of HA by month of amenorrhea (absence of menstruation)

    Time frame: 3 months

  2. Vascular dysfunction

    Measured by reactive hyperemic index (RHI)

    Time frame: 3 months

  3. Psychosocial stress

    Measured by NIH PROMIS® short-form questionnaires

    Time frame: 3 months

  4. Perceived stress

    Measured by the validate perceived stress scale questionnaire, a 10-item questionnaire, scores range from 0 to 40; higher scores indicate higher levels of perceived stress.

    Time frame: 3 months

  5. Step count

    Measured by Fitbit Versa 2 watch that tracks steps per day, active and resting heart rate, sleep hours per day

    Time frame: 3 months

  6. Physical activity level

    Measured by Fitbit Versa 2 watch that tracks amount of light physical activity, moderate, and vigorous activity

    Time frame: 3 months

  7. Heart Rate

    Measured by Fitbit Versa 2 watch that tracks heart rate

    Time frame: 3 months

  8. Caloric intake and nutrition

    Measured using a self-reported food diary

    Time frame: 3 days

  9. Vascular inflammation

    concentration of cytokines multiplex immunoassay platform

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Nov 29, 2022
StartActual
Jan 17, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05629377
Lead sponsor
Mayo Clinic
Responsible party
Chrisandra L. Shufelt, MD (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Nov 29, 2022
Start date
Jan 17, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Jun 4, 2026

Study contacts

Chrisandra Shufelt, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion